Briumvi is a medicine for treating adults with relapsing forms of multiple sclerosis (a disease of the brain and spinal cord in which inflammation destroys the protective covering around nerves and damages the nerves), where the patient has flare-ups (relapses) followed by periods with milder or no symptoms. It is used in patients with active disease, which means that they have relapses and/or signs of active inflammation on scans. Briumvi contains the active substance ublituximab.
Therapeutic Indication
### Therapeutic indication Briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
Therapeutic Area (MeSH)
ATC Code
L04
ATC Item
免疫抑制剂
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
EMA Name
Briumvi
Medicine Name
Briumvi
Aliases
N/ANo risk management plan link.
